1. Long-term use of pharmacological treatment in Alzheimer's disease: a retrospective cohort study in real-world clinical practice.
- Author
-
Lombardi, G, Lombardi, N, Bettiol, A, Crescioli, G, Ferrari, C, Lucidi, G, Polito, C, Berti, V, Bessi, V, Bagnoli, S, Nacmias, B, Vannacci, A, and Sorbi, S
- Subjects
DISEASE progression ,BIOMARKERS ,ALZHEIMER'S disease ,MEMANTINE ,ACADEMIC medical centers ,CONFIDENCE intervals ,CHOLINESTERASE inhibitors ,RETROSPECTIVE studies ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,PROPORTIONAL hazards models ,LONGITUDINAL method - Abstract
Purpose: To assess the impact of long-term use of different drugs commonly prescribed in Alzheimer's disease (AD) on its clinical course and to identify clinical and therapeutic factors associated with a delay in AD progression. Methods: We retrospectively enrolled 50 patients visited at the Neurology Unit, Careggi University Hospital (Florence), followed for at least 24 months. AD diagnosis was made according to clinical diagnostic criteria for probable/possible AD dementia, always supported at least by one biomarker. Clinical features, MMSE scores evaluated at diagnosis and every 6 months, and AD drugs used for at least 6 months, were recorded. Cox regression analysis was performed to estimate the hazard ratio (HR) for AD progression, assuming as the "final event," the progression to a more severe disease stage, defined as the achievement of an MMSE score less than 10. Results: At baseline, the median MMSE score was 22. During follow-up (median of 41 months), 56% of patients progressed to a more severe disease stage. The use of memantine, either alone (HR 0.24; 95% CI 0.09–0.60) or combined with acetylcholinesterase inhibitors (HR 0.35; 95% CI 0.14–0.88) and a higher MMSE score at baseline (HR 0.82; 95% CI 0.70–0.96) were associated with a significantly lower risk of AD progression. Conclusion: Nowadays, effective disease-modifying therapy for AD is missing. Nevertheless, when the diagnosis is established, our results support the advantage of long-term use of available pharmacological treatments, especially in combination, in delaying AD progression to its more severe disease stage. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF